ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 261 • 2015 ACR/ARHP Annual Meeting

    Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-Center Experience

    Serdal Ugurlu1, Bilgesu Ergezen2 and Huri Ozdogan2, 1Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey, Istanbul, Turkey, 2Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose: To review the patients followed in our center with FMF who received anakinra, an anti IL-1 receptor antagonist, because of insufficient colchicine response.  Methods: FMF…
  • Abstract Number: 262 • 2015 ACR/ARHP Annual Meeting

    Canakinumab Therapy in Patients with Familial Mediterranean Fever

    Serdal Ugurlu1, Emire Seyahi2, Gulen Hatemi2, Aysa Hacioglu1, Humeyra Ozcan1, Fatma Nihan Akkoc1 and Huri Ozdogan2, 1Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose: It has been  reported that Canakinumab reduced the frequency of attacks in  patients with Familial Mediterranean Fever (FMF) resistant to colchicine  with no apparent…
  • Abstract Number: 263 • 2015 ACR/ARHP Annual Meeting

    Use of Serum Ferritin and Heme Oxygenase 1 for the Diagnosis of Adult-Onset Still’s Disease: A Preliminary Report of Multicenter Study

    Yohei Kirino1, Yasushi Kawaguchi2, Yoshifumi Tada3, Seiji Minota4, Toshiyuki Ota5, Kohei Nagasawa6, Hiroshi Tsukamoto7, Syuji Takei8,9, Takahiko Horiuchi10, Hiroki Takahashi11, Hisae Ichida2, Masahiro Iwamoto4, Atsuhisa Ueda1, Akihide Ohta12, Yoshiaki Ishigatsubo1,13 and Hypercytokinemia Study Group, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 3Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, 4Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 5Department of Rheumatology, Iizuka Hospital, Iizuka, Japan, 6Rheumatic Disease Center, Sawara Hospital, Fukuoka, Japan, 7First Dept of Internal Med, Kyushu University, Fukuoka, Japan, 8School of Health Sciences, Faculty of Medicine,, Kagoshima University, Kagoshima City, Japan, 9School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, 10Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 11epartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, 12Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan, 13Yokosuka Rheumatic Diseases Center, Yokosuka City Hospital, Yokosuka, Japan

    Background/Purpose: Yamaguchi's criteria for classification of adult-onset Still's disease (AOSD) has been widely applied in clinic despite it was established decades ago.  However, hyperferritinemia, which…
  • Abstract Number: 264 • 2015 ACR/ARHP Annual Meeting

    Clinical Phenotype and Response to Treatment in Adult-Onset Still’s Disease with MEFV Variants

    Fumiaki Nonaka1, Toshimasa Shimizu2, Katsumi Eguchi3, Masataka Umeda4, Yukitaka Ueki5, Keita Fujikawa6, Akinari Mizokami7, Munetoshi Nakashima8, Michio Yasunami9, Naoki Iwamoto4, Atsushi Kawakami2, Yuka Jiuchi10 and Kiyoshi Migita10, 1Department of Rheumatology and Metabloism, Sasebo City General Hospital, Sasebo, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, 4Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 5Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, 6Arthritis and Connective Tissue Disease, Isahaya Health Insurance General Hospital, Isahaya, Japan, 7Department of Rheumatology, Isahaya Health Insurance General Hospital, Isahaya, Japan, 8Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9Nagasaki University Institute of Tropical Medicine (NEKKEN), Nagasaki, Japan, 10Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan

    Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that has been recently classified as a polygenic autoinflammatory disorder. Patients with Familial Mediterranean Fever…
  • Abstract Number: 265 • 2015 ACR/ARHP Annual Meeting

    Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still’s Disease. Multicenter Study of 75 Patients

    Leyre Riancho-Zarrabeitia1, Vanesa Calvo-Río1, Ricardo Blanco1, Jose L. Hernández2, Francisco Ortiz-Sanjuán1, Alejandro Olivé3, Anne Riveros Frutos4, Santos Castañeda5, Javier Narváez6, Maria Luisa Velloso Feijoo7, M. Victoria Hernández8, Alberto Sifuentes Giraldo9, Olga Maiz-Alonso10, Esteban Rubio Romero11, Cristina Mata-Arnaiz12, Adela Gallego Flores13, Jordi del Blanco14, Catalina Gómez-Arango15, Sara Manrique-Arija16, Maria Carmen Ordoñez17, Inmaculada Ros Vilamajo18, Miguel Angel Caracuel-Ruiz19, Mercedes Freire20, Jose Llobet21, Carlos Marras22, Concepción Moll Tuduri23, Chamaida Plasencia24, Rosa Roselló25, Ana Urruticoechea26, Inmaculada Jiménez-Moleón27, José Antonio Bernal28, Vera Ortiz-Santamaría29, Juan Ramón De Dios30, Mireia Moreno31, Jordi Fiter32, Marina de los Riscos33, Patricia E. Carreira33, María José Rodríguez Valls Sr.34, Carmen Gonzalez-Vela35, Javier Loricera1, Natalia Palmou1 and Miguel Angel Gonzalez-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 2Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 3Rheumatology, Hospital U German Trias i Pujol, Badalona, Spain, 4Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 5Rheumatology, H.U. La Princesa, Madrid, Spain, 6Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 7H Valme, Sevilla, Spain, 8Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, 9Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, 10Rheumatology, HU Donostia, San Sebastián, Spain, 11Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 12Rheumatology, Hospital Laredo, Santander, Spain, 13Rheumatology, Hospital de Mérida, Mérida, Spain, 14Rheumatology, H Sant Jaume, Calella, Spain, 15Rheumatology, Hospital Basurto,, Santander, Spain, 16Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, 17HRU Carlos Haya, Malaga, Spain, 18Hospital Son Llàtzer, Palma de Mallorca, Spain, 19Plaza Cruz Roja, 1, Hospital Reina Sofia, Córdoba, Spain, 20Hospital Universitario Juan Canalejo, La Coruña, Spain, 21Hospital San Pau, Barcelona, Spain, 22Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 23H Mateu Orfila, Mahón, Spain, 24Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, 25H San Jorge, Huesca, Spain, 26Hospital Can Misses, Ibiza, Spain, 27Rheumatology, Hospital San Cecilio, Granada, Spain, 28Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 29Rheumatology, Hospital General. Granollers., Granollers, Spain, 30Rheumatology, HU Álava, Vitoria, Spain, 31Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, 32Rheumatology, HU Son Espases. Palma de Mallorca., Palma de Mallorca, Spain, 33Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 34Rheumatology, Rheumatolgy Unit. Hospital Jerez, Jerez, Spain, 35Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain

    Background/Purpose: Interleukin (IL)-1 and IL-6 are pivotal cytokines in the pathogenesis of adult-onset Still’s disease (AOSD). Our aim was to compare the efficacy and safety of…
  • Abstract Number: 266 • 2015 ACR/ARHP Annual Meeting

    Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases

    Seung Taek Song1, Jin Ju Kim2, Seung Lee1, Hye-Jin Jeong1, Il Woong Sohn2, Sung Won Lee2, Joo Hyun Lee3, Hyoun-Ah Kim4, Kwang-Hoon Lee5, Sang Tae Choi6, Eun Young Lee7, Kichul Shin8, Hoon-Suk Cha9 and Dae-Hyun Yoo10, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Department of Rheumatology, Ilsan Paik Hospital, Inje University, Goyang, South Korea, 4Ajou University Hospital, Suwon, South Korea, 5Dongguk University Ilsan Hospital, Goyang, South Korea, 6Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea, 7Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 8Seoul National University College of Medicine, Seoul, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Nonsteroidal anti-inflammatory drugs or corticosteroids are first-line drugs for treating AOSD.…
  • Abstract Number: 267 • 2015 ACR/ARHP Annual Meeting

    Association of CXCL10 and CXCL13 Levels with Disease Activity and Cutaneous Manifestation in Active Adult-Onset Still’s Disease

    Hyoun-Ah Kim1, In Je Kim2, Jae Ho Han3, Chang-Hee Suh1 and Juyang Jung1, 1Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, 3Department of Pathology, Ajou University School of Medicine, Suwon, South Korea

    Background/Purpose: CXCL10 is produced in response to interferon-γ, and tumor necrosis factor-α (TNF-α) triggers the accumulation of activated lymphocytes. CXCL13 is constitutively expressed in secondary…
  • Abstract Number: 268 • 2015 ACR/ARHP Annual Meeting

    TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still’s Disease and Their Association with Disease Activity and Clinical Manifestations

    Hyoun-Ah Kim1, In Je Kim2, Jae Ho Han3, Juyang Jung4, Chang-Hee Suh4 and You-Sun Kim5, 1Department of Rheumatology, Ajou University School of Medicine, Suwan, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, 3Department of Pathology, Ajou University School of Medicine, Suwon, South Korea, 4Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 5Department of Biochemistry and Molecular biology, Ajou University School of Medicine, Suwon, South Korea

    Background/Purpose: S100A8 and S100A9 are two calcium-binding proteins that belong to the S100 family, and those are expressed by infiltrating monocytes and neutrophils under inflammatory…
  • Abstract Number: 269 • 2015 ACR/ARHP Annual Meeting

    Items of Yamaguchi Criteria Might be Associated with Disease Severity and Prognosis in Adult-Onset Still’s Disease

    Umut Kalyoncu1, Dilek Solmaz2, Hakan Emmungil3, Ayten Yazici4, Timucin Kasifoglu5, Gezmis Kimyon6, Ayse Balkarli7, Cemal Bes8, Mustafa Ozmen9, Fatma Alibaz-Oner10, Sukran Erten11, Yonca Cagatay12, Gozde Cetin13, Sedat Yılmaz14, Fatih Yildiz15, Omer Nuri Pamuk16, Orhan Kucuksahin17, Levent Kilic1, Abdulsamet Erden1, Veli Yazisiz18, Omer Karadag1, Suleyman Serdar Koca19, Mutlu Hayran20, Servet Akar2, Kenan Aksu21, Nurullah Akkoc22, Gokhan Keser23, Emel Gonullu24, Bunyamin Kisacik25, Ahmet Mesut Onat25, Mehmet Soy26, Nevsun Inanc27, Haner Direskeneli28, Mehmet Sayarlioglu29, Eren Erken30, Murat Turgay31, Ayse Cefle32, Ihsan Ertenli1 and Salih Pay33, 1Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Rheumatology, Dokuz Eylül University Faculty of Medicine, Izmir, Turkey, 3Rheumatology, Ege University Faculty of Medicine, Izmir, Turkey, 4Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, 5Rheumatology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey, 6Department of Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 7Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, 8Rheumatology, Bolu Izzet Baysal School of Medicine, Bolu, Turkey, 9Rheumatology, Izmir Ataturk Research and Training Hospital, Izmir, Turkey, 10Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 11Rheumatology, Ataturk Training and Research Hospital, Ankara, Turkey, 12Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, 13Rheumatology, Sutcu Imam University Faculty of Medicine, Kahramanmaras, Turkey, 14PsART study group, Ankara, Turkey, 15Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, 16Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 17Rheumatology, Yildirim Beyazit University School of Medicine, Ankara, Turkey, 18Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey, 19İnternal Medicine Division of Rheumatology, Firat University, Faculty of Medicine, Elazig, Turkey, 20Preventive Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 21Rheumatology, Ege University School of Medicine, Izmir, Turkey, 22Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, 23Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 24Rheumatology, Osmangazi University, Faculty of Medicine, Eskisehir, Turkey, 25Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 26Rheumatology, Abant Izzet Baysal University Faculty of Medicine, Bolu, Turkey, 27Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, 28Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey, 29Department of Internal Medicine Division of Rheumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey, 30Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, 31Internal Medicine-Rheumatology, Ankara University School of Medicine, Ankara, Turkey, 32Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 33Rheumatology, Gulhane School of Medicine, Ankara, Turkey

    Background/Purpose: Widely accepted outcome measures for disease activity and severity at Adult Onset Still's Disease (AOSD) is not developed until now. Predictive factors for worse…
  • Abstract Number: 270 • 2015 ACR/ARHP Annual Meeting

    Biologic Agents in Refractory Adult Still’s Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab

    Bahtiyar Toz1, Murat Inanc1, Burak Erer2, Nihan Senturk3, Sevil Kamali2, Lale Ocal2 and Ahmet Gul2, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Istanbul Unıversity, Istanbul Faculty of Medicine, Department of Internal Medicine, istanbul, Turkey

    Background/Purpose: There is no randomized controlled trial data to guide us for the management of Adult Still’s Disease (AOSD) patients refractory to conventional treatments. We…
  • Abstract Number: 271 • 2015 ACR/ARHP Annual Meeting

    Investigating an Auto-Inflammatory Component of COPD That Contributes to Progressive Decline in Lung Function Despite Smoking Cessation

    Pankti Shah1, Andrew Osterburg2, Rebeca Nelson3, Ben Yaniv3, Mauricio Orozco-Levi4 and Michael Borchers3, 1Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, 2Internal Medicine Pulmonary Division, University of Cincinnati Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH, 4IMIM Hospital del Mar Medical Research Institute, Barcelona, Spain

    Background/Purpose: Most Chronic Obstructive Pulmonary Disease (COPD) cases result from amplification of normal inflammatory responses due to noxious stimuli like cigarette smoke. Yet, the mechanism by…
  • Abstract Number: 272 • 2015 ACR/ARHP Annual Meeting

    Are the Autoimmune/Inflammatory Syndrome Induced By Adjuvants (ASIA) and the Undifferentiated Connective Tissue Disease (UCTD) Related to Each Other? a Case-Control Study of Environmental Exposures

    Francesco Scanzi1, Laura Andreoli1, Maria Martinelli1, Mara Taraborelli2, Ilaria Cavazzana1, Roberta Ottaviani1, Nice Carabellese1, Flavio Allegri1, Franco Franceschini1, Nancy Agmon-Levin3, Yehuda Shoenfeld4 and Angela Tincani1, 1Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel, 4Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Background/Purpose: The Autoimmune/Inflammatory Syndrome induced by adjuvants (ASIA) [1] is an entity that includes different autoimmune conditions observed after exposure to an adjuvant. Patients with…
  • Abstract Number: 273 • 2015 ACR/ARHP Annual Meeting

    Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study

    Maria Garcia-Gonzalez, Esmeralda Delgado-Frias, Sagrario Bustabad, Ivan Ferraz-Amaro and Beatriz Rodriguez-Lozano, Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: In recent years there has been a growing interest in establishing the concept of Undifferentiated CTD (UCTD) and defining its clinical evolution. Remarkable are…
  • Abstract Number: 274 • 2015 ACR/ARHP Annual Meeting

    Shrinking Lung Syndrome in Connective Tissue Disease

    Helena Borrell Paños1, Javier Narváez2, Juan José Alegre3, Ivan Castellvi4, Francesca Mitjavila5, Eulalia Armengol1, Joan Miquel Nolla1 and Maria Molina6, 1Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 4Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: Shrinking lung syndrome (SLS) is a rare a little known complication associated with systemic lupus erythematosus (SLE) and other connective tissue diseases (CTDs). This…
  • Abstract Number: 275 • 2015 ACR/ARHP Annual Meeting

    A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease Vs. Idiopathic Pulmonary Fibrosis

    Sandra Chartrand1, Lina Peykova2, Jeffery J. Swigris3 and Aryeh Fischer4, 1Université de Montréal, Montreal, QC, Canada, 2Rheumatology, National Jewish Health, Denver, CO, 3National Jewish Health, Denver, CO, 4University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: We compared clinical features, longitudinal pulmonary physiology, and survival among 3 groups of patients evaluated at our center between February 2008 to August 2014:…
  • « Previous Page
  • 1
  • …
  • 1705
  • 1706
  • 1707
  • 1708
  • 1709
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology